Summary
Depression is not only a common disorder, but also one that is readily treatable. Antidepressant drugs play a major role in treatment, although concurrent use of electroconvulsive therapy or psychotherapy may be indicated for some patients. Antidepressant drugs have been most specifically beneficial for patients with ‘endogenous’ depressions, but they should be used whenever this type of depression cannot be definitely ruled out. Besides the older tricyclic anti-depressants and monoamine oxidase inhibitors, a new ‘second generation’ group of drugs is now available. Although these drugs offer no great therapeutic advantages over the older ones, they may prove to have a more acceptable profile of side effects, may act more quickly, and may show less cardiotoxicity with overdoses. Whether one can classify depression pathogenetically according to various biological markers, such as urinary excretion of the norepinephrine metabolite, 3-methoxy-4-hydroxy phenylglycol, is still uncertain. At present, the choice of antidepressant drug for an individual patient is largely empirical. Besides being useful for treating depression, antidepressants may be used for treating enuresis, chronically painful states, obsessive-compulsive-phobic states, acute panic attacks and cataplectic attacks in narcoleptics.
Many studies have tried to define a therapeutic range of plasma concentrations of these drugs, so as to afford a better basis for dosing, but routine monitoring of drug plasma concentrations is seldom needed; the primary indication for doing so would be in the patient who has received what should be an adequate dose but who is still unresponsive. The value of maintenance treatment with antidepressants has been clearly established; the pattern it takes is best determined by the natural history of the disorder in individual patients.
Most drug interactions with antidepressants are pharmacodynamic in nature and can be managed by adjusting doses. Pharmacokinetic interactions with various sympatholytic antihypertensive drugs, such as guanethidine, methyldopa and clonidine, are rare but may be serious.
Patients with depression may be spared a considerable amount of discomfort, morbidity, and possibly mortality, by judicious use of antidepressant drugs and the other treatments currently available.
Similar content being viewed by others
References
Aberg, A. and Holmberg, G.: Preliminary clinical test of zimelidine (H 102/09), a new 5-HT uptake inhibitor. Acta Psychiatrica Scandinavica 59: 45–58 (1979).
Alkalay, D.; Wagner, W.E. Jr; Carlsen, S.; Khemani, L.; Volk, J.; Bartlett, F. and LeSher, A.: Bioavailability and kinetics of maprotiline. Clinical Pharmacology and Therapeutics 27: 697–703 (1980).
Alvan, G.; Borga, O.; Lind, M.; Palmer, L. and Siwers, B.: First pass hydroxylation of nortriptyline: concentrations of parent drug and metabolites in plasma. European Journal of Clinical Pharmacology 11: 219–224 (1977).
Amsterdam, J.; Brunswick, D.J. and Mendels, J.: High dose desipramine, plasma drug levels and clinical response. Journal of Clinical Psychiatry 40: 141–143 (1979).
Bannerjee, S.P.; Kung, L.S.; Riggi, S.J. and Ghanda, S.K.: Development of β-adrenergic receptor subsensitivity by anti-depressants. Nature 268: 455–456 (1977).
Beckman, H. and Goodwin, F.K.: Antidepressant response to tricyclics and urinary MHPG in unipolar patients. Archives of General Psychiatry 32: 17–21 (1975).
Bigger, J.T. Jr.; Giardina, E.G.V.; Perel, J.M.; Kantor, S.J. and Glassman, A.H.: Cardiac antiarrhythmic effect of imipramine hydrochloride. New England Journal of Medicine 296: 206–208 (1977).
Biggs, J.T. and Ziegler, V.E.: Protriptyline plasma levels and clinical response. Clinical Pharmacology and Therapeutics 22: 269–273 (1977).
Bopp, B. and Biel, J.H.: Antidepressant drugs. Life Sciences 14: 415–423 (1974).
Braithwaite, R.A.; Goulding, R.; Theano, G.; Bailey, J. and Coppen, A.: Plasma concentration of amitriptyline and clinical response. Lancet 1: 1297–1300 (1972).
Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 16: 273–301 (1978).
Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Nomifensine: A review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 18: 1–24 (1979).
Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Trazodone: A review of its pharmacological properties and therapeutic efficacy in depression. Drugs 21: 401–429 (1981).
Carasso, R.L.; Yehuda, S. and Streifler, M.: Clomipramine and amitriptyline in the treatment of severe pain. International Journal of Neuroscience 9: 191–194 (1979).
Casarino, J.P.: Neuropathy associated with amitriptyline. New York State Journal of Medicine 77: 2124–2126 (1977).
Chermat, R.; Simon, P. and Boissier, J.R.: Amoxapine in experimental psychopathology: A neuroleptic or an antidepressant. Arzneimittel-Forschung 29: 814–820 (1979).
Coppen, A.; Ghose, K.; Montgomery, S.; Rama Rao, V.A.; Bailey, J. and Jorgensen, A.: Continuation therapy with amitriptyline in depression. British Journal of Psychiatry 133: 28–33 (1978).
Crombie, D.L.; Pensent, R.J. and Fleming, D.: Imipramine in pregnancy. British Medical Journal 1: 745 (1972).
Davidson, J.; McLeod, M.N. and White, H.L.: Inhibition of platelet monoamine oxidase in depressed subjects treated with phenelzine. American Journal of Psychiatry 135: 470–472 (1978).
Davies, R.K.; Tucker, G.J.; Harrow, M. et al.: Confusional episodes and antidepressant medication. American Journal of Psychiatry 128: 127–131 (1971).
Davis, J.M.: Overview: maintenance therapy in psychiatry. II. Affective disorders. American Journal of Psychiatry 133: 1–13 (1976).
Davis, J.L.; Lewis, S.B.; Gerich, J.E.; Kaplan, R.A.; Schultz, T.A. and Wallin, J.D.: Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. Journal of the American Medical Association 238: 2291–2292 (1977).
Dawling, S.; Braithwaite, R.A.; McAuley, R. and Montgomery, S.A.: Single oral dose pharmacokinetics of clomipramine in depressed patients. Postgraduate Medical Journal 56(Suppl. 1): 115–116 (1980).
Della Corte, L; Broadhurst, A.D.; Sgaragli, G.P.; Filippini, S.; Heeley, A.F.; James, H.D.; Faravelli, C. and Pazzagli, A.: A clinical response and tricyclic plasma levels during treatment with clomopramine. British Journal of Psychiatry 134: 390–400 (1979).
Fabre, L.F. and McLendon, D.M.: A double-blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression. Current Therapeutic Research 27: 474–482 (1980).
Fann, W.E.; Cavanaugh, J.H.; Kaufmann, J.S.: Doxepin: Effects on transport of biogenic amines in man. Psychopharmacologia 22: 111–125 (1971).
Garver, D.L. and Davis, J.M.: Biogenic amine hypothesis of affective disorders. Life Sciences 24: 383–394 (1979).
Georgotas, A.; Mann, J.; Bush, D. and Gershon, S.: A clinical trial of zimelidine in depression. Communications in Psychopharmacology 4: 71–77 (1980).
Gershon, Rickels and Silvestrini (Eds) Trazodone: A new Broad-Spectrum A ntidepressant. Proceedings of a Symposium held in Vienna, during the 11th Congress of the Collegium Internationale Neuro-Psychopharmacologicum, July 9th–14th, 1978 (Excerpta Medica, Amsterdam 1980).
Glassman, A.H.; Perel, J.M. and Shostak, M.: Clinical implications of imipramine plasma levels for depressive illness. Archives of General Psychiatry 34: 197–204 (1977).
Gram, L.F. and Christiansen, J.: First pass metabolism of imipramine in man. Clinical Pharmacology and Therapeutics 17: 555–563 (1975).
Gram, L.F.; Christiansen, J. and Overo, K.F.: Pharmacokinetic interaction between tricyclic antidepressants and other psychopharmaca. Acta Psychiatrica Scandinavica 243 (Suppl): 52–53 (1973).
Gram, L.F. and Overo, K.F.: First-pass metabolism of nortriptyline in man. Clinical Pharmacology and Therapeutics 18: 305–314 (1975).
Granacher, R.P. and Baldessarini, R.J.: Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and anti-Parkinsonian drugs. Archives of General Psychiatry 32: 375–380 (1975).
Heiman, E.M.: Cardiac toxicity of thioridazine-tricyclic antidepressant combination. Journal of Nervous and Mental Disease 165: 139–143 (1977).
Hekimian, L.J.; Friefhoff, A.J. and Deever, E.: A comparison of the onset of action and therapeutic efficacy of amoxapine and amitriptyline. Journal of Clinical Psychiatry 39: 633–637 (1978).
Hollister, L.E.: Treatment of depression with drugs. Annals of Internal Medicine 89: 78–84 (1978).
Hollister, L.E.: Monitoring tricyclic antidepressant plasma concentrations. Journal of the American Medical Association 241: 2530–2533 (1979).
Hollister, L.E.; Overall, J.E.; Pokorny, A.D. and Shelton, J.: Acetophenazine and diazepam in anxious depressions. Archives of General Psychiatry 24: 273–278 (1971).
Hollister, L.E.; David, K.L.; Overall, J.E. and Anderson, T.: Excretion of MHPG in normal subjects. Implications for biological classification of affective disorders. Archives of General Psychiatry 35: 1410–1415 (1978).
Hollister, L.E.; Pfefferbaum, A. and Davis, K.L.: Monitoring nortriptyline plasma concentrations. American Journal of Psychiatry 137: 485–486 (1980).
Hordern, A. and Wheatley, D.: The black cloud: the recognition and treatment of endogenous depression in general practice. Medical Journal of Australia 1: 637–643 (1972).
Hrdina, P.D.; Rovei, V.; Henry, J.F.; Hervy, M.P.; Gomeni, R.; Forette, F. and Morselli, P.L.: Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. Psychopharmacology 70: 29–34 (1980).
Jaffe, K. and Ziscook, S.: Galactorrhea in a patient treated with amoxapine. Journal of Clinical Psychiatry 39: 821 (1978).
Johnson, D.A.W.: A study of the use of antidepressant medication in general practice. British Journal of Psychiatry 125: 186–192 (1974).
Kass, E.J.; Diokno, A.C. and Montealegre, A.: Enuresis: Principles of management and result of treatment. Journal of Urology 121: 794–796 (1979).
Kiloh, LG.; Andrews, G.; Neilson, M. and Bianchi, G.N.: The relationship of the syndromes called endogenous and neurotic depression. British Journal of Psychiatry 121: 193–196 (1972).
Kotin, J.; Post, R.M. and Goodwin, F.K.: Drug treatment of depressed patients referred for hospitalization. American Journal of Psychiatry 130: 1139–1141 (1973).
Kragh-Sorensen, P.; Hvidberg, E.F.; Hansen, C.E. and Baastrup, P.C.: Therapeutic control of plasma concentrations and long-term effect of nortriptyline in recurrent affective disorders. Pharmakipsychiatrie Neuropsychopharmakologie 9: 178–182 (1976a).
Kragh-Sorensen, P.; Hansen, C.E.; Baastrup, P.C. and Hvidberg, E.F.: Self-inhibiting action of nortriptyline’s antidepressive effect at high plasma levels. Psychopharmacologia 45: 305–312 (1976b).
Kupfer, D.J.; Hanin, I.; Spiker, D.G.; Grau, T. and Coble, P.: Amitriptyline plasma levels and clinical response in primary depression. Clinical Pharmacology and Therapeutics 22: 904–911 (1977).
Luzecky, M.H.; Burman, K.D. and Schultz, E.R.: The syndrome of inappropriate secretion of antidiuretic hormone associated with amitriptyline administration. Southern Medical Journal 67: 495–497 (1974).
Maas, J.W.: Biogenic amines and depression. Archives of General Psychiatry 32: 1367–1371 (1975).
Messiha, F.S. and Morgan, J.P.: Imipramine-mediated effects on levodopa metabolism in man. Biochemical Pharmacology 23: 1503–1507 (1974).
Moir, DC; Cornwell, W.B.; Fordyce, I.D.; Crooks, J.; O’Malley, K. and Turnbull, M.J.: Cardiotoxicity of amitriptyline. Lancet 2: 561–564 (1972).
Morris, J.B. and Beck, A.T.: The efficacy of antidepressant drugs. Archives of General Psychiatry 30: 667–674 (1974).
Morrow, A.W.: Limb deformities associated with iminodibenzyl hydrochloride. Medical Journal of Australia 1: 658–659 (1972).
Montgomery, S.; Braithwaite, R.; Dawling, S. and McAuley, R.: High plasma nortriptyline levels in the treatment of depression. Clinical Pharmacology and Therapeutics 23: 309–314 (1978).
Montgomery, S.A.; McAuley, R.; Rani, S.J.; Montgomery, D.B.; Braithwaite, R. and Dawling, S.: Amitriptyline plasma concentration and clinical response. British Medical Journal 1: 230–231 (1979).
Moody, J.P.; Whyte, S.F.; MacDonald, A.J. and Maylor, G.J.: Pharmacokinetic aspects of protriptyline plasma levels. European Journal of Clinical Pharmacology 11: 51–56 (1977).
Nagy, A. and Johansson, R.: The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. Psychopharmacology 54: 125–131 (1977).
Newton, R.W.: Physostigmine salicylate in the treatment of tricyclic antidepressant overdosage. Journal of the American Medical Association 231: 941–943 (1975).
Nies, A.; Robinson, D.S.; Friedman, M.J.; Green, R.; Cooper, T.B.; Ravaris, C.L. and Ives, J.O.: Relationship between age and tricyclic antidepressant levels. American Journal of Psychiatry 134: 790 (1977).
Overo, K.F.; Gram, L.F. and Hansen, V.: Kinetics of nortriptyline in man according to a two compartment model. European Journal of Clinical Pharmacology 8: 343–347 (1975).
Paykel, E.S.; Mueller, P.S. and de la Vergne, P.M.: Amitriptyline. weight gain and carbohydrate craving: a side effect. British Journal of Psychiatry 123: 501–507 (1973).
Pinder, R.M.; Brogden, R.N.; Speight, T.M. and Avery, G.S.: Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states. Drugs 13: 321–352 (1977a).
Pinder, R.M.; Brogden, R.N.; Speight, T.M. and Avery, G.S.: Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 13: 401–421 (1977b).
Potter, W.Z.; Muscettola, G. and Goodwin, F.K.: Binding of imipramine to plasma protein and to brain tissue: relationship to CSF tricyclic levels in man. Psychopharmacology 63: 187–192 (1979).
Prien, R.F.; Klett, C.J. and Caffey, E.M. Jr.: Lithium carbonate and imipramine in prevention of affective episodes. Archives of General Psychiatry 29: 420–425 (1973).
Reisby, N.; Gram, L.F.; Bech, P.; Nagy, A.; Odden Petersen, G.; Ortmann, J.; Ibsen, I.; Dencker, S.J.; Jacobsen, O.; Krautwald, O.; Sondergaard, I. and Christiansen, J.: Clinical effects of pharmacokinetic variability. Psychopharmacology 54: 263–272 (1977).
Risch, S.C.; Huey, L.Y. and Jenowsky, D.S.: Plasma levels of tricyclic antidepressants and clinical efficacy: Review of the literature — Part 1. Journal of Clinical Psychiatry 40: 4–16 (1979).
Robinson, D.S. and Barker, E.: Tricyclic antidepressant cardiotoxicity. Journal of the American Medical Association 236: 2089–2090 (1976).
Robinson, D.S.; Nies, A.; Ravaris, C.L. and Lamborn, K.R.: The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states: a controlled clinical trial. Archives of General Psychiatry 29: 407–413 (1973).
Rogers, S.C. and Clay, P.M.: A statistical review of controlled trials of imipramine and placebo in the treatment of depressive illness. British Journal of Psychiatry 127: 599–603 (1975).
Sathanathan, G.L and Gershon, S.: Imipramine withdrawal: an akathisia-like syndrome. American Journal of Psychiatry 130: 1286–1287 (1973).
Schildkraut, J.J.: Toward a biochemical classification of depressive disorders: I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depression. Archives of General Psychiatry 35: 1427–1433 (1978).
Schiesser, M.A.; Winokur, G. and Sherman, B.M.: Genetic subtypes of unipolar primary depressive illness distinguished by hypothalamic-pituitary-adrenal axis activity. Lancet 1: 739–741 (1979).
Sethna, E.R.: A study of refractory cases of depressive illness and their response to combined antidepressant treatment. British Journal of Psychiatry 124: 265–273 (1974).
Shaw, D.M.: The practical management of affective disorders. British Journal of Psychiatry 130: 432–451 (1977).
Simon, P.; LeCrubier, Y.; Jouvent, J.; Puech, A.J.; Allilaire, J.F. and Widlöcher, D.: Experimental and clinical evidence of the antidepressant effect of a beta-adrenergic stimulant. Psychological Medicine 8: 335–338 (1978).
Sjoqvist, F.: Clinical use of drug plasma level determinations; in Azarnoff, Hollister and Shand (Eds) 1977 Yearbook of Drug Therapy, pp. 13–20 (Year Book Medical Publishers, Chicago 1977).
Sorensen, B.; Kragh-Sorensen, P.; Larsen, N-E. and Hvidberg, E.F.: The practical significance of nortriptyline plasma control. Psychopharmacology 59: 35–39 (1978).
Stein, M.K.; Rickeis, K. and Wiese, C.C.: Maintenance therapy with amitriptyline: a controlled trial. American Journal of Psychiatry 137: 370–371 (1980).
Stern, S.L.; Rush, A.J. and Mendels, J.: Toward a rational pharmacotherapy of depression. American Journal of Psychiatry 137: 545–552 (1980a).
Stern, R.S.; Marks, I.M.; Wright, J. and Luscombe, D.K.: Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis. Postgraduate Medical Journal 56(Suppl. 1): 134–139 (1980b).
Stewart, M.A.: Treatment of bedwetting. Journal of the American Medical Association 232: 281–283 (1975).
Vandel, S.; Vandel, B.; Sandoz, M.; Allers, G.; Bechlel, P. and Volmat, R.: Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline. European Journal of Clinical Pharmacology 14: 185–190 (1978).
Vetulani, J. and Sulser, F.: Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 257: 495–496 (1975).
van Spanning, H.W. and van Zwiewten, P.A.: The interference of tricyclic antidepressants with the central hypotensive effect of clonidine. European Journal of Pharmacology 24: 402–404 (1973).
Wilson, I.C.; Loosen, P.T.; Pettus, C.W.: A double-blind clinical comparison of amoxapine, imipramine and placebo in the treatment of depression. Current Therapeutic Research, Clinical and Experimental 22: 620–627 (1977).
Ziegler, V.E.; Co, B.T.; Taylor, J.R.; Clayton, P.J. and Biggs, J.T.: Amitriptyline plasma levels and therapeutic response. Clinical Pharmacology and Therapeutics 19: 795–801 (1976).
Ziegler, V.E.; Biggs, J.T.; Ardekani, A.B. and Rosen, S.H.: Contribution to the pharmacokinetics of amitriptyline. Journal of Clinical Pharmacology 18: 462–467 (1978a).
Ziegler, V.E.; Biggs, J.T.; Wylie, L.T.; Rosen, S.H.; Hawf, DJ. and Coryell, W.H.: Doxepin kinetics. Clinical Pharmacology and Therapeutics 23: 573–579 (1978b).
Zis, A.P. and Goodwin, F.W.: Novel antidepressants and the biogenic amine hypothesis of depression. The case for iprindole and mianserin. Archives of General Psychiatry 36: 1097–1107 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hollister, L.E. Current Antidepressant Drugs: Their Clinical Use. Drugs 22, 129–152 (1981). https://doi.org/10.2165/00003495-198122020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198122020-00003